PLSE
Pulse Biosciences Inc
$
15.730
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
16.770
Open
14.950
VWAP
15.79
Vol
117.92K
Mkt Cap
1.07B
Low
14.950
Amount
1.86M
EV/EBITDA(TTM)
--
Total Shares
55.23M
EV
996.07M
EV/OCF(TTM)
--
P/S(TTM)
--
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
Show More
Valuation Metrics
The current forward P/E ratio for Pulse Biosciences Inc (PLSE.O) is -12.05, compared to its 5-year average forward P/E of -9.65. For a more detailed relative valuation and DCF analysis to assess Pulse Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-9.65
Current PE
-12.05
Overvalued PE
-2.66
Undervalued PE
-16.65
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
103.24
Current PS
16.27
Overvalued PS
312.51
Undervalued PS
-106.04
Financials
Annual
Quarterly
FY2025Q3
86.00K
Total Revenue
FY2025Q3
YoY :
+49.15%
-20.37M
Operating Profit
FY2025Q3
YoY :
+52.88%
-19.39M
Net Income after Tax
FY2025Q3
YoY :
+38.10%
-0.29
EPS - Diluted
FY2025Q3
YoY :
+44.57%
-13.10M
Free Cash Flow
FY2025Q3
-224.42
Gross Profit Margin - %
FY2025Q3
-56.74K
FCF Margin - %
FY2025Q3
-22.54K
Net Margin - %
FY2025Q3
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.3M
USD
8
3-6
Months
485.7K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
871.0K
USD
1
Bought
0-3
1
508.1K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
3
2.7M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.3M
USD
8
3-6
Months
485.7K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
871.0K
USD
1
Bought
0-3
1
508.1K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
3
2.7M
USD
Months
PLSE News & Events
Events Timeline
2025-10-24 (ET)
2025-10-24
07:30:13
Pulse Biosciences initiates NANOCLAMP AF study with first patient enrollment
2025-09-08 (ET)
2025-09-08
07:04:53
Pulse Biosciences Receives FDA Approval for Investigational Device Exemption
2025-09-02 (ET)
2025-09-02
07:03:15
Pulse Biosciences initiates first procedures in study on benign thyroid nodules
Sign Up For More Events
Sign Up For More Events
News
3.0
10-24NASDAQ.COMOur Calculations Show ISCG Could Reach $64
5.0
10-16NewsfilterPulse Biosciences Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
9.0
10-10NewsfilterPulse Biosciences to Present Late-Breaking Findings from First-in-Human Feasibility Study of nPulse™ Cardiac Surgical System at 39th Annual Meeting of the European Association for Cardio-Thoracic Surgery
Sign Up For More News
People Also Watch
FWRG
First Watch Restaurant Group Inc
17.240
USD
-3.90%
IHS
IHS Holding Ltd
6.410
USD
-3.32%
BOW
Bowhead Specialty Holdings Inc
25.070
USD
-3.28%
SSTK
Shutterstock Inc
21.970
USD
-4.06%
PDFS
PDF Solutions Inc
27.490
USD
-2.00%
LPG
Dorian LPG Ltd
27.170
USD
-8.12%
KFRC
Kforce Inc
30.290
USD
-2.26%
COLL
Collegium Pharmaceutical Inc
40.660
USD
+13.42%
SII
Sprott Inc
84.140
USD
+0.19%
FAQ
What is Pulse Biosciences Inc (PLSE) stock price today?
The current price of PLSE is 15.73 USD — it has decreased -3.32 % in the last trading day.
What is Pulse Biosciences Inc (PLSE)'s business?
What is the price predicton of PLSE Stock?
What is Pulse Biosciences Inc (PLSE)'s revenue for the last quarter?
What is Pulse Biosciences Inc (PLSE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Pulse Biosciences Inc (PLSE)'s fundamentals?
How many employees does Pulse Biosciences Inc (PLSE). have?